The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats

Journal of Physiology and Pharmacology

Volumn 49, Issue 2, 1998, Pages 251-260

  Chabielska, E ^a,b   Pawlak, R ^a   Golatowski, J ^a   Buczko, W ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Medical University   (Poland)

Author keywords

Animal thrombosis model; Captopril; Losartan; Primary hemostasis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ANIMAL MODEL; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEMOSTASIS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE COUNT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BLEEDING TIME; BLOOD PLATELETS; BLOOD PRESSURE; CAPTOPRIL; LOSARTAN; MALE; RATS; RATS, WISTAR; RECEPTORS, ANGIOTENSIN; THROMBOSIS;

EID: 0031825308     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985; 72: 406-412.
2. Pfeffer MA, Braunwald E, Moie LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.
3. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-1973.
4. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 5: 1353-1362.
5. Nishimura H, Tsuji H, Masuda H et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997; 77: 1189-1195.
6. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996; 93: 1073-1078.
7. Wright RA, Flapan AD, Alberti KG, Ludlam CA, Fox KA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73.
8. Mombouli JV, Vanhoutte PM. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol 1992; 20: Suppl. 9, S74-S83.
9. Timmermans PBMWM, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmol Rev 1993; 45: 205-251.
10. Tsunoda K, Abe K, Hagino T et al. Hypotensive effects of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28-32.
11. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
12. Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995; 26: 236-243.
13. Pawlak R, Chabielska E, Buczko W. Antithrombotic effect of enalapril, an angiotensin-converting enzyme inhibitor, on venous thrombosis in rats. Pol J Pharmacol 1996; 48: 117-120.
14. Chabielska E, Pawlak R, Buczko W. Effects of drugs affecting the renin-angiotensin system on venous thrombosis in normotensive rats. Pol J Pharmacol 1996; 48: 89-91.
15. Hornstra G, Vandelmans-Starrenburg A. Induction of experimental arterial occlusive thrombi in rats. Atherosclerosis 1972; 17: 369-382.
16. Ikeda K, Nara Y, Yamori Y. Indirect systolic and mean blood pressure determination by a new tail cuff method in spontaneously hypertensive rats. Lab Anim 1991; 25: 26-29.
17. Dejana E, Villa S, de Gaetano G. Bleeding time in rats: A comparison of different experimental conditions. Thromb Haemost 1982; 48: 108-111.
18. Chabielska E, Kolpakov V, D'Adamo MC et al. Morphological and hemostatic changes in rats with abdominal arterial prosthesis. Thromb Res 1996; 82: 69-77.
19. Pawłowska Z, Pluskota E, Chabielska E et al. Phosphorothioate oligodeoxyribonucleotides antisense to PAI-1 mRNA increase fibrinolysis and modify experimental thrombosis in rats. Thromb Haemost 1998; 79: 384-353.
20. Chabielska E, Pawlak R, Buczko W. Losartan does not influence the blood platelet aggregation in normotensive rats. Acta Physiol Hung 1996; 84: 271-272.
21. Reyers I, Mussoni L, Donati MB, de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1978; 18: 669-674.
22. Hornstra G, Kalafusz R, Wierts JW, Kester ADM. Does platelet function in vitro reflect thrombosis tendency in vivo? Thromb Haemost 1991; 65: 1085.
23. Reyers I, de Gaetano G, Donati MB. Prolongation by warfarin of "template" bleeding time in rats: A vitamin K-dependent effect (42253). Proc Soc Exp Biol Med 1986; 181: 275-276.
24. Iacoviello L, D'Adamo MC, Pawlak K et al. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Thromb Haemost 1996; 76: 1102-1107.
25. Maffrand JP, Bernat A, Delebassee D, Defreyn G, Cazenave JP, Gordon JL. ADP plays a key role in thrombogensis in rats. Thromb Haemost 1988; 59: 225-230.
26. Reyers I, de Gaetano G, Donati MB. Warfarin anticoagulation prevents experimental arterial thrombosis in rats without inducing haemorrhage. Thromb Res 1983; 29: 465-468.
27. 2 - receptor in endothelial cells and isolated ischemic rat hearts. Pharm and Pharmacol Lett 1993; 3: 24-27.
28. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-1058.
29. Pawlak R, Chabielska E, Golatowski J, Buczko W. Mechanism of antithrombotic action of captopril in venous thrombosis in normotensive rats. Haemostasis 1996; 26: Suppl. 3, 381.
30. 1 receptor antagonist, in experimental model of venous thrombosis in spontaneously hypertensive rats. Naunyn-Schmideberg's Arch Pharmacol 1997; 356: Suppl. 1, R43.
31. Stamler JS, Jaraki O, Osborne J et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U.S.A. 1992; 89: 7674-7677.
32. Lidbury PS, Korbut R, Vane JR. Sodium nitroprusside modulates the fibrinolytic system in the rabbit. Br J Pharmacol 1990; 101: 527-530.
33. Someya N, Kodama K, Tanaka K. Effect of captopril on plasma prostacyclin concentration in essential hypertensive patients. Prostagland Leukot Med 1985; 20: 187-195.
34. Jaiswal N, Diz DI, Tallant A, Khosla MC, Ferrario CM. The nonpeptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin synthesis. Am J Hypertens 1991; 4: 228-233.